Shares of Avid Bioservices CDMO rose 6.81% after the company reported Q1 results.
Quarterly Results
Earnings per share rose 175.00% over the past year to $0.06, which beat the estimate of ($0.07).
Revenue of $25,392,000 higher by 66.46% year over year, which beat the estimate of $16,500,000.
Outlook
The company is confirming revenue guidance for the full fiscal year 2021 of $76 million to $81 million.
How To Listen To The Conference Call
Date: Sep 01, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/64ateurd
Price Action
52-week high: $8.82
52-week low: $3.02
Price action over last quarter: Up 19.72%
Company Description
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.